

Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke

Saifudeen Ismael,¹ Liang Zhao,¹ Sanaz Nasoohi,^{1,2} Tauheed Ishrat^{1,3*}

Effect of MCC950 on Cleaved IL-18 and IL-1 β at 24 h after MCAO




Figure 1: Expression of Cleaved IL-18 and IL-1 β following treatment with MCC950, 24 h post-MCAO. There was no difference in the expression of IL-1 β and IL-18 in response to MCAO and MCC950 treatment

Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke

Saifudeen Ismael,¹ Liang Zhao,¹ Sanaz Nasoohi,^{1,2} Tauheed Ishrat^{1,3*}

All Full-length Blots




Figure 2: Expression of NLRP3 inflammasome components(A) NLRP3 (B), Cleaved caspase-1 (C), ASC (D) and IL-1 β , following treatment with MCC950, 24 h post-MCAO.

Sham: 1, 4, 7, 10, 13; TMCAO: 2, 5, 8, 11, 14, 16; TMCAO+MCC950: 3, 6, 9, 12, 15, 17

The representative images used in manuscript are highlighted with box.





Figure 3: Expression of phospho-NFkBP65 and NFBp65 (A) phospho-IkB α (B) following treatment with MCC950, 24 h post-MCAO. Sham: 1, 4, 7, 10, 13; TMCAO: 2, 5, 8, 11, 14, 16; TMCAO +MCC950: 3, 6, 9, 12, 15,

The representative images used in manuscript are highlighted with box.




Figure 4: Expression of TNF α , following treatment with MCC950, 24 h post-MCAO.

Sham: 1, 4, 7, 10, 13; **TMCAO:** 2, 5, 8, 11, 14, 16; **TMCAO+MCC950:** 3, 6, 9, 12, 15, 17

The representative images used in manuscript are highlighted with box.




Figure 5: Expression of (A) Cleaved PARP and (B) Cleaved caspase 3, following treatment with MCC950, 24 h post-MCAO.

Sham: 1, 4, 7, 10, 13; **TMCAO:** 2, 5, 8, 11, 14, 16; **TMCAO+MCC950:** 3, 6, 9, 12, 15, 17

The representative images used in manuscript are highlighted with box.